Cyclo Therapeutics (Cyclo Therapeutics) Total Liabilities : $6.55 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Cyclo Therapeutics Total Liabilities?

Cyclo Therapeutics's Total Liabilities for the quarter that ended in Mar. 2024 was $6.55 Mil.

Cyclo Therapeutics's quarterly Total Liabilities increased from Sep. 2023 ($6.65 Mil) to Dec. 2023 ($8.49 Mil) but then declined from Dec. 2023 ($8.49 Mil) to Mar. 2024 ($6.55 Mil).

Cyclo Therapeutics's annual Total Liabilities declined from Dec. 2021 ($3.85 Mil) to Dec. 2022 ($3.48 Mil) but then increased from Dec. 2022 ($3.48 Mil) to Dec. 2023 ($8.49 Mil).

Cyclo Therapeutics Total Liabilities Historical Data

The historical data trend for Cyclo Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclo Therapeutics Total Liabilities Chart

Cyclo Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

3.18

3.74

3.85

3.48

8.49

Cyclo Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															4.54	6.13	6.65	8.49	6.55

Cyclo Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Cyclo Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	8.468	+	(0.022	+	0.00099999999999969
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	8.49

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	13.248	-	4.757
	=	8.49

Cyclo Therapeutics's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	6.536	+	(0.018	+	6.8348104953486E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	6.55

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	7.164	-	0.61
	=	6.55

Cyclo Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Cyclo Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyclo Therapeutics (Cyclo Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cyclo Therapeutics Inc (NAS:CYTH) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

6714 North West 16th Street, Suite B, Gainesville, FL, USA, 32653

Website

https://www.cyclodex.com

Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company develops cyclodextrin-based products for the treatment of disease. Its drug candidate, Trappsol Cyclo, treats Niemann-Pick Type C disease (NPC). Its other products include Trappsol HPB, Trappsol Fine Chemical, and Aquaplex.

Executives

Vivien Wong	director	6C CHATEAUX CIRCLE, SCARSDALE NY 10583
Rafael Holdings, Inc.	10 percent owner	520 BROAD STREET, NEWARK NJ 07120
William Conkling	director	C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Jeffrey Tate	director, officer: Chief Executive Officer	C/O CTD HOLDINGS, INC., 27317 NW 78TH AVENUE, HIGH SPRINGS FL 32643
Francis Patrick Ostronic	director	932 HUNGERFORD DRIVE, SUITE 28A, ROCKVILLE MD 20850
Markus Sieger	director	BEUTSTWEG 12, CH-8032, ZURICH V8 000000000
N Scott Fine	director	600 3RD AVE, NEW YORK NY 10016
Sharon Hemond Hrynkow	officer: SVP for Medical Affairs	4816 KING SOLOMON DRIVE, ANNADALE VA 22003
Lise Lund Kjems	officer: Chief Medical Officer	91 ROLLINGWOOD LN., CONCORD MA 01742
Joshua M Fine	officer: Chief Financial Officer	21 HEMMELSKAMP ROAD, WILTON CT 06897
Armistice Capital Master Fund Ltd.	10 percent owner	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Michael Eric Lisjak	officer: Chief Regulatory Officer	12 ROOSEVELT AVENUE, OLD GREENWICH CT 06870
Steven Boyd	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
L.p. Novit,	10 percent owner	966 HUNGERFORD DRIVE, ROCKVILLE MD 20850